Company intelligence / Profile preview
Koçak Farma
- Ownership
- Private
- Employees
- ~1850
- Development stage
- Commercial
Overview
Koçak Farma has over 600 products on the market with a strong focus on oncology—producing one in every two cancer drugs sold in Turkey. The company was the first to launch biosimilars such as enoxaparin sodium and insulin analogues in Turkey. It holds EU GMP certification and exports both APIs and finished products globally. Its R&D center develops monoclonal antibodies and vaccines alongside conventional small molecules[1][2][6].
- Therapeutic areas
- CardiovascularMen's HealthMetabolic DisordersRheumatologyWomen's HealthOncologyInfectious Diseases
- Modalities
- Small moleculeMonoclonal antibodyBiosimilarVaccineProtein
- Industry
- Biotech
Drug pipeline
1 assetPartnerships
Beyond the preview
Go deeper on Koçak Farma.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Koçak Farma.